Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.33 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976502 | 0.95 | SLC2A1 (0.34) | SLC2A1SLC2A3ACACBCNR2GAA | |
| SCHEMBL23975995 | 0.88 | ACACB (0.36) | SLC2A1SLC2A3ACACB | |
| SCHEMBL30225254 | 0.88 | ACACB (0.36) | SLC2A1SLC2A3ACACB | |
| SCHEMBL24702214 | 0.87 | SLC2A1 (0.31) | SLC2A1SLC2A3ACACB | |
| SCHEMBL24702435 | 0.86 | SLC2A1 (0.30) | SLC2A1SLC2A3 | |
| SCHEMBL30118830 | 0.86 | MEN1 (0.35) | SLC2A1SLC2A3GAAMAPK1RECQL | |
| SCHEMBL23975778 | 0.84 | MEN1 (0.37) | SLC2A1SLC2A3CNR2GAAMAPK1 | |
| SCHEMBL30118714 | 0.84 | MEN1 (0.37) | SLC2A1SLC2A3CNR2GAAMAPK1 | |
| SCHEMBL23976164 | 0.84 | ACACB (0.32) | ACACBCNR2GAAMAPK1RECQL | |
| SCHEMBL23976160 | 0.84 | ACACB (0.32) | ACACBCNR2GAAMAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |